Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06846515 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
A Phase 3 study of Gout and Hyperuricemia, sponsored by Arthrosi Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 750
- Enrollment target
- 20
- Study locations
NCT06846515: Active Phase 3 study of Gout and Hyperuricemia, sponsored by Arthrosi Therapeutics.
NCT06846515 is a Phase 3 study of Gout and Hyperuricemia that is active but no longer recruiting, run by Arthrosi Therapeutics. The registered enrollment target is 750 participants, below the 8,866-participant average among 34 other Gout trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06846515, a Phase 3 study of Gout and Hyperuricemia, is active but no longer recruiting, sponsored by Arthrosi Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 750 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Primary Outcome
Comparison of the treatment groups for the proportion of patients with serum urate (uric acid) (sUA) level \< 6 mg/dL at month 6
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AR882 75 mg
- DRUG AR882 50 mg
Study Locations (20)
California
- Arthrosi Investigative Site (614) - Garden Grove
- Arthrosi Investigative Site (618) - La Mesa
- Arthrosi Investigative Site (687) - La Mesa
- Arthrosi Investigative Site (655) - La Palma
- Arthrosi Investigative Site (632) - Lincoln
- Arthrosi Investigative Site (605) - Lomita
- Arthrosi Investigative Site (675) - Long Beach
- Arthrosi Investigative Site (603) - Santa Monica
- Arthrosi Investigative Site (672) - Tarzana
- Arthrosi Investigative Site (656) - Thousand Oaks
Colorado
- Arthrosi Investigative Site (660) - Aurora
- Arthrosi Investigative Site (669) - Colorado Springs
- Arthrosi Investigative Site (612) - Fort Collins
Alabama
- Arthrosi Investigative Site (620) - Birmingham
- Arthrosi Investigative Site (616) - Huntsville
Arizona
- Arthrosi Investigative Site (680) - Peoria
- Arthrosi Investigative Site (640) - Phoenix
Florida
- Arthrosi Investigative Site (665) - Cooper City
- Arthrosi Investigative Site (613) - Jupiter
Arkansas
- Arthrosi Investigative Site (617) - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2025-03-11 |
| Est. Completion | 2026-04 |
| Phase | Phase 3 |
What the registry record for NCT06846515 still lists
NCT06846515 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, below the 8,866-participant average among 34 other Gout trials with a reported enrollment target (92% lower).
The record links to 4 conditions, with Gout appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06846515 names 20 study sites across 6 states, led by California, Colorado, Alabama.
Frequently Asked Questions
What is clinical trial NCT06846515 about?
NCT06846515 is a clinical study titled "Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)". This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
What is the current status of trial NCT06846515?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 750 participants. The study started on 2025-03-11. Estimated completion is 2026-04.
What conditions does trial NCT06846515 study?
This clinical trial studies the following conditions: Gout, Hyperuricemia, Gout Chronic, Arthritis, Gouty.
What interventions are being tested in trial NCT06846515?
The interventions under investigation include: Placebo (DRUG), AR882 75 mg (DRUG), AR882 50 mg (DRUG).
Who is sponsoring clinical trial NCT06846515?
This trial is sponsored by Arthrosi Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06846515 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06846515's enrollment target sits among peer trials
750 3rd of 34 higher than 31 of 34 other Gout trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gout trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Dotinurad Versus Allopurinol in Participants With Gout
RECRUITING · Phase 3
-
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)
ACTIVE NOT RECRUITING · Phase 3
-
Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout
COMPLETED · Phase 3
-
Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout
COMPLETED · Phase 3
-
Combining Lesinurad With Allopurinol in Inadequate Responders
COMPLETED · Phase 3
-
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI